European journal of clinical investigation
-
Eur. J. Clin. Invest. · Apr 2020
Systemic redox imbalance in patients with nonalcoholic fatty liver disease.
Oxidative stress is one of the major pathologic mechanisms for the progression of nonalcoholic fatty liver disease (NAFLD). The aim of this study was to evaluate the relationship between the extent of steatosis and oxidative stress parameters in patients with NAFLD. ⋯ Increased extent of hepatic steatosis could be considered as a pathological mechanism for enhancing oxidative stress in patients with NAFLD, independent of obesity, and is exacerbated further in patients with more severe condition.
-
Eur. J. Clin. Invest. · Mar 2020
Coronavirus disease 2019: the harms of exaggerated information and non-evidence-based measures.
The evolving coronavirus disease 2019 (COVID-19) pandemic1 is certainly cause for concern. Proper communication and optimal decision-making is an ongoing challenge, as data evolve. ⋯ This can lead to inappropriate actions. It is important to differentiate promptly the true epidemic from an epidemic of false claims and potentially harmful actions.
-
Eur. J. Clin. Invest. · Feb 2020
Randomized Controlled TrialFGF23 and the PTH response to paricalcitol in chronic kidney disease.
The parathyroid glands are endowed both with receptors responsive to FGF23 and to 1,25 vitamin D. Vitamin D receptor (VDR) activation, besides lowering PTH, also raises serum FGF23. FGF23 has been implicated in parathyroid resistance to VDR activation but the issue has never been investigated in predialysis CKD patients. ⋯ Serum FGF23 and PTH are inter-related and changes in the Ca × P product induced by paricalcitol per se correlate with the FGF23 response to this drug. Independently of serum FGF23, the parathyroid glands of patients with moderate to severe CKD maintain an intact ability to respond to VDR activation.